Clinical trials: Hydroxychloroquine
Pre-diabetes
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology…
- Trial name
- NCT01326533
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pittsburgh
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine.
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01649947
- Testing
- Paclitaxel, Carboplatin, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rutgers, The State University of New Jersey
Frontal Fibrosing Alopecia, Cicatricial Alopecia
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often used to treat FFA, but it is not…
- Trial name
- NCT07190534
- Testing
- Hydroxychloroquine (HCQ), Methotrexate (MTX)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Crohn's Disease
Antibiotics and Hydroxychloroquine in Crohn's
There is growing evidence that Crohn's disease may be caused by replication of bacteria, perhaps particularly E. coli, within macrophages (a specialized sort of white blood cell).
- Trial name
- APRiCCOT (NCT01783106)
- Testing
- Ciprofloxacin, Doxycycline, Hydroxychloroquine
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Royal Liverpool University Hospital
Rheumatoid Arthritis
Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
This is an international (Sweden, Finland, Norway, Denmark, Iceland and the Netherlands) trial designed to compare the safety and efficacy of active conventional therapy (ACT) and three biologic treatments in subjects with early…
- Trial name
- NCT01491815
- Testing
- Non-biological DMARD's, Cimzia, Orencia
- Where
- 30 sites in Denmark, Finland and 4 more
- Volunteers
- 812 people
- Sponsor
- Karolinska Institutet
Rheumatoid Arthritis, Insulin Resistance
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA).
- Trial name
- RA PLUS (NCT01132118)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- TAQE (NCT05842174)
- Testing
- Hydroxychloroquine, Lipiodol
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Rheumatoid Arthritis
Montelukast Use in Rheumatoid Arthritis
Montelukast is widely used in patients with asthma. Several preclinical data suggest that it could be repositioned as novel strategy for managing rheumatic patients by decreasing inflammatory mediators.
- Trial name
- NCT05447520
- Testing
- Montelukast, Conventional DMARDs
- Where
- Egypt
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Noha Mansour
Connective Tissue Diseases, Pregnancy Related
The Clinical Features and Pregnancy Outcomes of CTD Patients
Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on.
- Trial name
- NCT04918524
- Testing
- Prednisone, Hydroxychloroquine, Aspirin
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Qilu Hospital of Shandong University
Metastatic Colorectal Cancer
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).
- Trial name
- NCT05843188
- Testing
- Hydroxychloroquine, Irinotecan, Leucovorin
- Where
- 2 sites in Canada
- Volunteers
- 155 people
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis C
Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.
The study is aimed to investigate the safety, tolerability and efficacy of a fixed dose combination therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (PEG-IFN alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C…
- Trial name
- NCT01272310
- Testing
- Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
- Volunteers
- 36 people
- Sponsor
- Sheba Medical Center
Advanced Adenocarcinoma, Metastatic Adenocarcinoma
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of Hydroxychloroquine (HCQ) to a commonly-used front-line therapy of pancreatic cancer, gemcitabine/nab-paclitaxel.
- Trial name
- NCT01506973
- Testing
- Hydroxychloroquine (HCQ), Gemcitabine, Abraxane
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pre-Exposure Prophylaxis, Coronavirus
Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?
On 11 March 2020, the World Health Organization declared SARS-CoV-2 (commonly called COVID-19) a global pandemic. As in any pandemic, maintaining the health and safety of the healthcare workforce is of great importance as health…
- Conditions
- Pre-Exposure Prophylaxis, Coronavirus, SARS-CoV 2
- Trial name
- HEROs (NCT04374942)
- Testing
- Hydroxychloroquine
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Megan Landes
Primary Sjögren Syndrome, Vaginitis Candida
Sjögren and Gynecologic Considerations
Sjögren's syndrome is an autoimmune disorder characterized by glandular and extra-glandular manifestations. It is called primary Sjögren's syndrome (pSS) in absence of another connective tissue disease.
- Conditions
- Primary Sjögren Syndrome, Vaginitis Candida, Vaginitis, Sexual Dysfunction
- Trial name
- NCT05670535
- Testing
- Visual analogue scale (VAS) for dyspareunia, Visual analogue scale (VAS) for vaginal dryness, The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Ankara City Hospital Bilkent
Gastrointestinal Cancer
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
This research study is for patients with an advanced cancer that carries a mutation in a gene called KRAS. Genes are parts of our DNA which carry instructions for a cell (the smallest component of an body part).
- Trial name
- MEKiAUTO (NCT04214418)
- Testing
- Cobimetinib, Hydroxychloroquine, Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
COVID
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19.
- Trial name
- OUTCOV (NCT04365582)
- Testing
- Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab
- Sponsor
- Fondation Hôpital Saint-Joseph
Covid19
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.
- Trial name
- NCT04349592
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- Qatar
- Volunteers
- 456 people
- Sponsor
- Hamad Medical Corporation
HIV Infections
Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients
The purpose of this pilot study is to find out if taking hydroxychloroquine will decrease immune activation (stimulation of the body's defence system) in people with early HIV infection.
- Trial name
- HCQ-01 (NCT01067417)
- Testing
- Hydroxychloroquine
- Volunteers
- 83 people
- Sponsor
- Medical Research Council
Sudden Hearing Loss
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours.
- Trial name
- NCT06467526
- Testing
- Hydroxychloroquine, Steroid
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Rheumatoid Arthritis
Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region
The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia…
- Trial name
- NCT00422227
- Testing
- Etanercept , Methotrexate, Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
- Where
- 27 sites in Hong Kong, India and 6 more
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer